News About: Pharm. Industry
Yooyoung to introduce Nippon Shinyaku’s NS-126Yooyoung Pharm and Nippon Shinyaku Co. have recently announced an exclusive license agreement, under which Yooyoung will acquire exclusive rights in Korea to develop and commerc...
|
Positive list system re-emerging as contentious issueThe government is firm in pushing for drug pricing reform, which it says cannot be the subject of transparency as it is part of the country's healthcare policies that ensure the...
|
Korean drug makers fared well in ethical sales
The nation’s major pharmaceutical firms, including Daewoong Pharm and Hanmi Pharm, increased their share of the pie in the domestic ethical market last year, according to EDI claims tallied by the Health Insurance Rev...
Battle looms over Plavix and Lipitor market
Korea’s major drug makers and two multinational companies – Pfizer and Sanofi-Aventis - are set for a fresh battle for leadership in the domestic prescription Plavix and Lipitor markets.
1) Plavix
The country's ge...
Hanmi, emerging as strong competitor in domestic generic market
Hanmi Pharm is expected to grab bigger pie in the nation’s generic market where many players are rushing to introduce first generic versions of off-patent drugs, according to a local analyst.
Kim Tae-hee, an analys...
Johnson & Johnson's four affiliated firms moving to one building
Janssen Korea, Johnson & Johnson Korea, Johnson & Johnson Medical Korea and VisionCare have been incorporated into a 28-story LS Tower building in Yongsan District.
A total of 1,000 employees may enjoy easier commu...
Korean pharmaceutical firms seeking to acquire promising bioventure companies
Domestic drug makers are focusing on investment or acquisition for promising biopharmaceutical companies with platform technologies as part of efforts to survive in an era of free trade deals with foreign countries.
...
Annual medication costs up 14% on average
Korea’s drug costs have risen an average 14.3 percent for the recent five years, according to a report released by the Health Insurance Review Agency.
The report shows that the national health insurance spent 9.2 t...
Lilly Korea announces KFDA approval of exenatideLilly Korea announce that the Korea Food and Drug Administration has approved exenatide as adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who...
|
EDQM approves EstechPharma’s acamprosate calcium
EstechPharma says the European Directorate for Quality Medicines (EDQM) has certified its acamprosate calcium, anti-alcoholic medicine.
With the EDQM’s approval of acamprosate calcium, the company is poised to make...
